We are developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.  

The Hedgehog Pathway Inhibitor program in collaboration with Genentech is our most advanced program with lead small molecule candidate, GDC-0449, currently being tested in a pivotal Phase II clinical trial in advanced basal cell carcinoma as well as Phase II clinical trials in first line metastatic colorectal cancer (in combination with bevacizumab and chemotherapy) and in advanced ovarian cancer (as a single agent maintenance therapy).  In addition, there are several additional Phase I and II clinical trials planned and ongoing under a collaboration between Genentech and the National Cancer Institute.

We have focused our internal resources on developing additional small molecule targeted cancer drug candidates.  We have selected CUDC-101, a first-in-class inhibitor of HDAC, EGFR and Her2 as a developmental candidate and have recently completed a Phase I clinical trial of this molecule. Our second candidate selected for development is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor, that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.

In addition, we have several programs that are in various stages of preclinical drug development.  Because of the early stages of development of these programs, our ability and that of our collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.